# Trial of Afatinib in Pediatric Tumours

> **NCT02372006** · PHASE1,PHASE2 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 56 (actual)

## Conditions studied

- Neuroectodermal Tumors
- Rhabdomyosarcoma

## Interventions

- **DRUG:** afatinib

## Key facts

- **NCT ID:** NCT02372006
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-04-29
- **Primary completion:** 2020-08-05
- **Final completion:** 2020-08-05
- **Target enrollment:** 56 (ACTUAL)
- **Last updated:** 2021-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02372006

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02372006, "Trial of Afatinib in Pediatric Tumours". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02372006. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*